Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2011

01-03-2011

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

Authors: Jaume Capdevila, Ramón Salazar, Irene Halperín, Albert Abad, James C. Yao

Published in: Cancer and Metastasis Reviews | Special Issue 1/2011

Login to get access

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms that require a multidisciplinary approach for an optimal management. The lack of effectiveness of traditional DNA-damaging agents has led to the exploration of new targeted drugs in order to exploit phenotypical features of GEP-NET therapy. However, due to the orphan setting of these tumors, deeper characterization of molecular features and pathways that characterize cell growth, apoptosis, angiogenesis, and invasion are lacking, particularly genetic mutations or epigenetic alterations that generate oncogenic dependency or even addiction. The PI3K-AKT-mTOR pathway has been implicated as having a crucial role in GEP-NETs not only due to the overexpression of several growth factors and their receptors that finally activate this axis but also hereditary syndromes with constitutive activation of the mTOR pathway with high incidence of GEP-NETs. In this article, we aim to review the recent development of the main molecules that target mTOR complex and have showed promising activity in the treatment of GEPNETs.
Literature
1.
Hansel, D. E., Rahman, A., Hermans, J., et al. (2003). Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Modern Pathology, 16(7), 652–659.PubMedCrossRef
2.
Zhang, J., Jia, Z., Li, Q., et al. (2007). Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer, 109(8), 1478–1486.PubMedCrossRef
3.
Furukawa, M., Raffeld, M., Mateo, C., et al. (2005). Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clinical Cancer Research, 11(9), 3233–3242.PubMedCrossRef
4.
Chaudhry, A., Papanicolaou, V., Oberg, K., et al. (1992). Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Research, 52(4), 1006–1012.PubMed
5.
Nilsson, O., Wangberg, B., Kolby, L., et al. (1995). Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. International Journal of Cancer, 60(5), 645–651.CrossRef
6.
Fjällskog, M. L., Lejonklou, M. H., Oberg, K. E., et al. (2003). Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clinical Cancer Research, 9(4), 1469–1473.PubMed
7.
Wulbrand, U., Remmert, G., Zofel, P., et al. (2000). mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. European Journal of Clinical Investigation, 30(8), 729–739.PubMedCrossRef
8.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004). The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews, 25(3), 458–511.PubMedCrossRef
9.
O’Toole, D., Couvelard, A., Rebours, V., et al. (2010). Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 17(4), 847–856.PubMedCrossRef
10.
Kolby, L., Persson, G., Franzen, S., et al. (2003). Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. The British Journal of Surgery, 90(6), 687–693.PubMedCrossRef
11.
Moertel, C. G., Rubin, J., & Kvols, L. K. (1989). Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. Journal of Clinical Oncology, 7(7), 865–868.PubMed
12.
Öberg, K., Norheim, I., Lind, E., et al. (1986). Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results. Cancer Treatment Reports, 70(11), 1297–1304.PubMed
13.
Dirix, L. Y., Vermeulen, P. B., Fierens, H., et al. (1996). Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors—an antiangiogenic effect? Anti-Cancer Drugs, 7(2), 175–181.PubMedCrossRef
14.
Rinke, A., Muller, H. H., Schade-Brittinger, C., et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology, 27(28), 4656–4663.PubMedCrossRef
15.
Moertel, C. G., Lefkopoulo, M., Lipsitz, S., et al. (1992). Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. The New England Journal of Medicine, 326(8), 519–523.PubMedCrossRef
16.
Kouvaraki, M. A., Ajani, J. A., Hoff, P., et al. (2004). Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology, 22(23), 4762–4771.PubMedCrossRef
17.
Sun, W., Lipsitz, S., Catalano, P., et al. (2005). Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology, 23(22), 4897–4904.PubMedCrossRef
18.
Öberg, K., & Jelic, S. (2009). Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Annals of Oncology, 20(Suppl 4), 150–153.PubMed
19.
Öberg, K., Kvols, L., Caplin, M., et al. (2004). Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology, 15(6), 966–973.PubMedCrossRef
20.
Capdevila, J., & Salazar, R. (2009). Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Target Oncology, 4(4), 287–296.CrossRef
21.
Wullschleger, S., Loewith, R., & Hall, M. N. (2006). TOR signaling in growth and metabolism. Cell, 124(3), 471–484.PubMedCrossRef
22.
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009). Targeting the mTOR signaling network for cancer therapy. Journal of Clinical Oncology, 27(13), 2278–2287.PubMedCrossRef
23.
Arcaro, A., & Guerreiro, A. S. (2007). The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Current Genomics, 8(5), 271–306.PubMedCrossRef
24.
Yuan, R., Kay, A., Berg, W. J., et al. (2009). Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Journal of Hematology and Oncology, 2, 45.PubMedCrossRef
25.
Vignot, S., Faivre, S., Aguirre, D., et al. (2005). mTOR-targeted therapy of cancer with rapamycin derivatives. Annals of Oncology, 16(4), 525–537.PubMedCrossRef
26.
Franke, T. F., Hornik, C. P., Segev, L., et al. (2003). PI3K/Akt and apoptosis: size matters. Oncogene, 22(56), 8983–8998.PubMedCrossRef
27.
Paez, J., & Sellers, W. R. (2003). PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treatment and Research, 115, 145–167.PubMedCrossRef
28.
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., et al. (2008). Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resistance Updates, 11(1–2), 32–50.PubMedCrossRef
29.
von Wichert, G., Jehle, P. M., Hoeflich, A., et al. (2000). Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Research, 60(16), 4573–4581.
30.
Van Gompel, J. J., & Chen, H. (2004). Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery, 136(6), 1297–1302.PubMedCrossRef
31.
Zatelli, M. C., Minoia, M., Martini, C., et al. (2010). Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocrine-Related Cancer, 17(3), 719–729.PubMedCrossRef
32.
Tee, A. R., Fingar, D. C., Manning, B. D., et al. (2002). Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proceedings of the National Academy of Sciences of the United States of America, 99(21), 13571–13576.PubMedCrossRef
33.
Verhoef, S., van Diemen-Steenvoorde, R., Akkersdijk, W. L., et al. (1999). Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. European Journal of Pediatrics, 158(4), 284–287.PubMedCrossRef
34.
Eledrisi, M. S., Stuart, C. A., & Alshanti, M. (2002). Insulinoma in a patient with tuberous sclerosis: Is there an association? Endocrine Practice, 8(2), 109–112.PubMed
35.
Dworakowska, D., & Grossman, A. B. (2009). Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocrine-Related Cancer, 16(1), 45–58.PubMedCrossRef
36.
Hattori, S., Maekawa, M., & Nakamura, S. (1992). Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21. Oncogene, 7(3), 481–485.PubMed
37.
Johannessen, C. M., Reczek, E. E., James, M. F., et al. (2005). The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proceedings of the National Academy of Sciences of the United States of America, 102(24), 8573–8578.PubMedCrossRef
38.
Blansfield, J. A., Choyke, L., Morita, S. Y., et al. (2007). Clinical, genetic and radiographic analysis of 108 patients with von Hippel–Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery, 142(6), 814–818. discussion 818 e1–2.PubMedCrossRef
39.
Forsythe, J. A., Jiang, B. H., Iyer, N. V., et al. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology, 16(9), 4604–4613.PubMed
40.
Woodward, E. R., & Maher, E. R. (2006). Von Hippel–Lindau disease and endocrine tumour susceptibility. Endocrine-Related Cancer, 13(2), 415–425.PubMedCrossRef
41.
Thakker, R. V. (2010). Multiple endocrine neoplasia type 1 (MEN1). Best Practice & Research. Clinical Endocrinology & Metabolism, 24(3), 355–370.CrossRef
42.
Debelenko, L. V., Zhuang, Z., Emmert-Buck, M. R., et al. (1997). Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Research, 57(11), 2238–2243.PubMed
43.
Jakobovitz, O., Nass, D., DeMarco, L., et al. (1996). Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. The Journal of Clinical Endocrinology and Metabolism, 81(9), 3164–3167.PubMedCrossRef
44.
Öberg, K. (2009). Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Current Opinion in Endocrinology, Diabetes and Obesity, 16(1), 72–78.CrossRef
45.
Wang, E. H., Ebrahimi, S. A., Wu, A. Y., et al. (1998). Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Research, 58(19), 4417–4420.PubMed
46.
Missiaglia, E., Dalai, I., Barbi, S., et al. (2010). Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Journal of Clinical Oncology, 28(2), 245–255.PubMedCrossRef
47.
48.
Durán, I., Kortmansky, J., Singh, D., et al. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer, 95(9), 1148–1154.PubMedCrossRef
49.
50.
Zitzmann, K., De Toni, E. N., Brand, S., et al. (2007). The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology, 85(1), 54–60.PubMedCrossRef
51.
Tabernero, J., Rojo, F., Calvo, E., et al. (2008). Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. Journal of Clinical Oncology, 26(10), 1603–1610.PubMedCrossRef
52.
Yao, J. C., Phan, A. T., Chang, D. Z., et al. (2008). Efficacy of RAD001 (Everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology, 26(26), 4311–4318.PubMedCrossRef
53.
Yao, J. C., Lombard-Bohas, C., Baudin, E., et al. (2010). Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology, 28(1), 69–76.PubMedCrossRef
54.
Pavel, M., Hainsworth, J.D., Baudin, E., et al. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus plus octreotide LAR vs ersus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). In: 35th European Medical Oncology Society; 2010; Milan, Italy.
55.
Yao, J.C., Shah, M.H., Ito, T., et al. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). In: 35th European Society Medical Oncology; 2010; Milan, Italy
Metadata
Title
Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors
Authors
Jaume Capdevila
Ramón Salazar
Irene Halperín
Albert Abad
James C. Yao
Publication date
01-03-2011
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue Special Issue 1/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-011-9290-3

Other articles of this Special Issue 1/2011

Cancer and Metastasis Reviews 1/2011 Go to the issue

ReviewPaper

Future perspectives on neuroendocrine tumors

ReviewPaper

Current knowledge on diagnosis and staging of neuroendocrine tumors

ReviewPaper

Somatostatin analogs for the treatment of neuroendocrine tumors

ReviewPaper

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

EditorialNotes

Gastroenteropancreatic neuroendocrine tumors. Where are we now?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits